Pacific Biosciences Of California (PACB) Cash & Current Investments (2010 - 2026)

Pacific Biosciences Of California's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $276.0 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 19.57% year-over-year to $276.0 million in Q1 2026; TTM through Mar 2026 was $276.0 million, a 19.57% decrease from a year earlier, with the FY2025 full-year figure at $63.7 million, up 2088.43% from the prior year.
• Cash & Current Investments advanced to $276.0 million in Q1 2026 per PACB's latest filing, from $63.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $874.9 million in Q1 2023 and bottomed at $2.9 million in Q4 2024.
• The 5-year median for Cash & Current Investments is $343.1 million (2025), against an average of $353.8 million.
• Across the five-year window, Cash & Current Investments tumbled 99.33% in 2023 and surged 13551.22% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $450.5 million in 2022, then tumbled by 99.33% to $3.0 million in 2023, then declined by 3.64% to $2.9 million in 2024, then soared by 2088.43% to $63.7 million in 2025, then soared by 333.04% to $276.0 million in 2026.
• Per Business Quant, the three latest PACB Cash & Current Investments figures stand at $276.0 million (Q1 2026), $63.7 million (Q4 2025), and $244.0 million (Q3 2025).